Why did Eli Lilly and Foghorn Therapeutics end their cancer partnership?

According to the article’s Oct. 1 roundup, Eli Lilly and Foghorn Therapeutics ended their partnership after a cancer drug disappointed in testing. The piece presents the split as the clearest sign that large pharma companies may quickly cut partnered oncology programs when clinical performance falls short.